ViGenCell Inc.
Financials
Valuation Metrics
ViGenCell Inc.'s Market Cap is ₩1166B. At end of 2025 it was ₩1999B. Ranked #1185 of 2,421 in KR market (top 49%), #634 of 1,640 on KOSDAQ (top 39%), #137 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 59%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 116.64B KRW | KR#1,185/2,421 Sec#137/231 |
| Revenue | 922.0M KRW | KR#2,387/2,421 Sec#219/231 |
| Net Income | -13.28B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 54.28B KRW | KR#2,170/2,421 Sec#194/231 |
| Net Assets | 43.72B KRW | KR#1,995/2,421 Sec#172/231 |
| Employees | 63 | KR#1,940/2,421 Sec#171/231 |
| Value | ||
| P/B | 2.67x | KR#2,069/2,421 Sec#161/231 |
| P/S | 126.51x | KR#2,395/2,421 Sec#212/231 |
| FCF Yield | -11.85% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -30.36% | KR#2,183/2,421 Sec#176/231 |
| ROA | -24.46% | KR#2,277/2,421 Sec#187/231 |
| Op. Margin | -1533.39% | KR#2,387/2,421 Sec#219/231 |
| Revenue Growth | 310.56% | KR#18/2,421 Sec#6/231 |
| Financial Health | ||
| Debt Ratio | 24.14% | KR#471/2,421 Sec#57/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | -13.82B KRW | KR#1,802/2,421 Sec#164/231 |
| Cash | 3.93B KRW | KR#2,093/2,421 Sec#196/231 |
| Current Ratio | 15.27x | KR#44/2,421 Sec#15/231 |
| Performance | ||
| 1Y Return | 49.93% | KR#260/2,421 Sec#12/231 |
| 1M Return | -1.22% | KR#1,375/2,421 Sec#104/231 |
| From 52W High | -67.22% | KR#2,124/2,421 Sec#175/231 |
| 1Y MDD | -71.96% | KR#2,065/2,421 Sec#179/231 |
| Trading | ||
| Volume | 106,978 shares | KR#751/2,421 Sec#69/231 |
| Trading Value | 616.9M KRW | KR#871/2,421 Sec#89/231 |
| Foreign Own. | 2.04% | KR#1,612/2,421 Sec#156/231 |
| Per Share | ||
| EPS | -648 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,133 KRW | KR#2,040/2,421 Sec#168/231 |
Company Info
Established in 2013, the company is a bio venture specializing in pharmaceutical research and development and immune cell therapy development. Based on HLA research from The Catholic University of Korea College of Medicine, it develops immunotherapies using human blood-derived immune cells and is a cell therapy specialist with domestic clinical trial experience in antigen-specific killer T-cell research. Utilizing its ViTier platform technology, the company is developing treatments for NK/T-cell lymphoma and acute myeloid leukemia. Vaxcell-Bio was established in 2013 and is headquartered in Seoul-si, Geumcheon-gu.